Topical Salmeterol Reduces Protein Content of Nasal Lavage Fluid in Response to Allergen and Histamine Challenge: Double-Blind Cross-over Placebo-Controlled Studies in Adults
| العنوان: | Topical Salmeterol Reduces Protein Content of Nasal Lavage Fluid in Response to Allergen and Histamine Challenge: Double-Blind Cross-over Placebo-Controlled Studies in Adults |
|---|---|
| المؤلفون: | Alison Moorat, Finbarr O'Connell, Jane Henderson, Loretta Jacques, Martin A. Birchall, R. W. Fuller, N. B. Pride |
| المصدر: | American Journal of Rhinology. 10:251-256 |
| بيانات النشر: | SAGE Publications, 1996. |
| سنة النشر: | 1996 |
| مصطلحات موضوعية: | Histamine challenge, business.industry, Pharmacology, medicine.disease_cause, Placebo, Protein content, 03 medical and health sciences, 0302 clinical medicine, Allergen, Otorhinolaryngology, 030220 oncology & carcinogenesis, Immunology, Salbutamol, Medicine, Nasal administration, Nasal Lavage Fluid, Salmeterol, 030223 otorhinolaryngology, business, medicine.drug |
| الوصف: | We have studied the effects of topical intranasal β-2-adrenoceptor agonists on nasal airflow resistance (Rnaw) and secretions. Pretreatment with salmeterol (SM) and salbutamol (SB) was given in two double-blind, placebo-controlled studies. In Protocol 1, 15 patients with allergic rhinitis were challenged with a threshold dose of allergen. Rnawand lavage fluid total protein, albumin, mucin, lysozyme, tryptase, histamine, and eosinophil cationic protein (ECP) were measured. In Protocol 2, 20 normal subjects were challenged with ascending doses of histamine and Rnawand lavage fluid total protein and albumin were measured. After allergen challenge, there was a significant, increase in Rnawtotal protein, albumin, and tryptase. SM significantly attenuated the rise in total protein (post-allergen challenge mean 218 mcg/mL, 95% c.i. 16–447; SB 344, 45–641; placebo 365, 105–725: P = 0.036). SM significantly reduced albumin concentration at 30 minutes post-drug (post-histamine challenge geometric mean 17.1 mcg/mL, interquartile range 8.2–29.4; SB 25.1, 15.2–43.0; placebo 24.2, 16.6–37.8: P = 0.027). SM has acute effects on the nasal response to allergen in allergic rhinitis and to histamine in normal subjects. These results imply an effect on glands and blood vessels in vivo that may represent part of the drug's clinical activity. |
| تدمد: | 1539-6290 1050-6586 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::7f7b7cdce463e57d9af32eabe1256cce https://doi.org/10.2500/105065896782103108 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi...........7f7b7cdce463e57d9af32eabe1256cce |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15396290 10506586 |
|---|